Lourens Bloem

Utrecht University

Netherlands

This profile is automatically generated from trusted academic sources.

Google Scholar

.

ORCID

.

LinkedIn

Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI

Contact this professor

LinkedIn

Google Scholar

Research Interests

Pharmacotherapy

100%

Pharmacology

60%

Drug Safety

60%

Drug Repurposing

60%

Cancer Therapy

40%

Pharmaceutical Policy

30%

Regulatory Affairs

30%

Ask ApplyKite AI

Start chatting

How can you help me contact this professor?

What are this professor's research interests?

How should I write an email to this professor?

Articles15

Feasibility of disease terminology systems for mapping orphan conditions and therapeutic indications of designated orphan medicines in the European Union

Year:

2024

Leftover of Amoxicillin Suspension After Use by Children in the Netherlands

Year:

2024

Agreement about Availability of Alternative Treatments for Innovative Drugs Assessed by the EMA and HTA Organizations

Year:

2024

A Natural Language Processing Approach Towards Harmonized Communication of Uncertainties Identified During the European Medicine Authorization Process

Year:

2024

High cost oncology drugs without proof of added benefit are burdening health systems

Year:

2024

Added benefit and revenues of oncology drugs approved by the European Medicines Agency between 1995 and 2020: retrospective cohort study

Year:

2024

Durvalumab after chemoradiotherapy in patients with stage III non-small-cell lung cancer: real-world outcomes versus clinical trial results

Year:

2023

European Conditional Marketing Authorization in a Rapidly Evolving Treatment Landscape: A Comprehensive Study of Anticancer Medicinal Products in 2006–2020

Year:

2023

Pre‐approval and post‐approval availability of evidence and clinical benefit of conditionally approved cancer drugs in Europe: A comparison with standard approved cancer drugs

Year:

2022

Towards diagnostic criteria for malignant deep penetrating melanocytic tumors using single nucleotide polymorphism array and next-generation sequencing

Year:

2022

Comprehensive evaluation of post-approval regulatory actions during the drug lifecycle – a focus on benefits and risks

Year:

2021

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies.

Year:

2021

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies

Year:

2021

Genome-wide copy number variations as molecular diagnostic tool for cutaneous intermediate melanocytic lesions: a systematic review and individual patient data meta-analysis.

Year:

2021

The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs

Year:

2020

Collaborators3

Rick Vreman

Utrecht University

NETHERLANDS

Toine Egberts

Utrecht University

NETHERLANDS

Paula van Hennik

Group Head Clinical Affairs

-

NETHERLANDS

Social connections

How do I reach out?

Sign in for free to see their profile details and contact information.

Meet Kite AI